Oslo, Norway 9 July 2021 – Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that Torbjørn Furuseth has notified the Company that he is resigning from his position as Chief Financial Officer to take a CEO position with a cancer diagnostics company.
Oystein Soug, CEO of Targovax, said: “I would like to thank Torbjørn for his leadership, dedicated work and his valuable contributions to Targovax. He has played an important role in developing and executing our company’s strategy. Torbjørn’s belief in the technology and future of Targovax is strong but taking a CEO role is a natural next step for him. On behalf of the Board and the Company, I wish him success in his new endeavor.”
Dr Furuseth will continue his work and responsibilities through September 30, 2021. The Company will find a replacement to continue the execution of Targovax’s financial strategies.
For further information, please contact:
Oystein Soug, CEO
Phone: +47 906 56 525
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients. Targovax’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The products are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging data in several indications, in monotherapy and in multiple combination, the next development steps for ONCOS-102 will involve a clinical trial with registration intent in checkpoint inhibitor refractory melanoma.